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Marijuana is the most widely used illicit drug among adolescents and young adults.
Unique cognitive, emotional, and social changes occur during this critical period of
development from childhood into adulthood. The adolescent brain is in a state of
transition and differs from the adult brain with respect to both anatomy (e.g., neuronal
connections andmorphology) and neurochemistry (e.g., dopamine, GABA, and glutamate).
These changes are thought to support the emergence of adult cerebral processes and
behaviors. The endocannabinoid system plays an important role in development by
acting on synaptic plasticity, neuronal cell proliferation, migration, and differentiation.
Delta-9-tetrahydrocanabinol (THC), the principal psychoactive component in marijuana,
acts as a partial agonist of the cannabinoid type 1 receptor (CB1R). Thus, over-activation of
the endocannabinoid system by chronic exposure to CB1R agonists (e.g., THC, CP-55,940,
and WIN55,212-2) during adolescence can dramatically alter brain maturation and cause
long-lasting neurobiological changes that ultimately affect the function and behavior of the
adult brain. Indeed, emerging evidence from both human and animal studies demonstrates
that early-onset marijuana use has long-lasting consequences on cognition; moreover,
in humans, this use is associated with a two-fold increase in the risk of developing a
psychotic disorder. Here, we review the relationship between cannabinoid exposure during
adolescence and the increased risk of neuropsychiatric disorders, focusing on both clinical
and animal studies.
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INTRODUCTION
According to the Substance Abuse and Mental Health Services
Administration, cannabis is the most commonly used drug of
abuse among adolescents; in 2010, as many as 20% of all 16-
year-olds surveyed reported using cannabis. Adolescence refers
to the developmental time period between childhood and adult-
hood and is generally considered to occur from 12 to 17 years
of age (Spear, 2000; Dahl, 2004). This period represents a critical
phase in development, characterized by strong neurobehavioral
plasticity and many maturation processes in the central ner-
vous system, includingmyelination, synaptic pruning, volumetric
growth, changes in receptor distribution, and programming of
neurotrophic levels (Giedd et al., 1999; Spear, 2000; Bartzokis
et al., 2001; Andersen, 2003). These changes occur primarily in
the prefrontal cortex (PFC) and limbic regions (Chechik et al.,
1999; Casey et al., 2000; Toga et al., 2006) and are believed to
support the emergence of adult behavior and cognitive functions
(Spear, 2000; Andersen, 2003).
Cannabinoid type 1 receptors (CB1R), type 2 receptors
(CB2R), and their endogenous ligands (endocannabinoids; eCBs)
anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) are
present and active during early brain development (Berghuis
et al., 2005, 2007; Mulder et al., 2008). The eCB systemmodulates
several neurodevelopmental processes, including the proliferation
and differentiation of progenitor cells, neuronal migration,
axonal guidance, fasciculation, positioning of cortical interneu-
rons, neurite outgrowth, and morphogenesis (Harkany et al.,
2007, 2008). In both adolescent humans and adolescent ani-
mals, the eCB system also undergoes functional development and
changes (Rodriguez de Fonseca et al., 1993; Mato et al., 2003;
Ellgren et al., 2008; Dalton and Zavitsanou, 2010; Eggan et al.,
2010). In humans, CB1R expression increases dramatically from
infancy to young adulthood in regions such as the frontal cor-
tex, striatum and hippocampus (Mato et al., 2003). While these
studies did not directly address specific phases of adolescence,
studies in rodents have provided further information on changes
in CB1R expression thatmay be regionally and temporally specific
(Ellgren et al., 2008). CB1R expression increases progressively in
the shell of the nucleus accumbens (NAcc) during adolescence,
but decreases in the core of the NAcc during this same period
(Ellgren et al., 2008). In the PFC, the expression of CB1R grad-
ually decreases from mid-adolescence to late-adolescence with
the greatest decreases observed in the cingulate, prelimbic, and
infralimbic cortices (Ellgren et al., 2008; Heng et al., 2011).
Concomitant to developmental changes in the CB1R, levels of
AEA and 2-AG vary throughout adolescence in a region- and
time-specific manner (Ellgren et al., 2008; Lee et al., 2013). There
is an AEA spike in the NAcc during mid-adolescence; while in
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the PFC AEA progressively increases across adolescence (Ellgren
et al., 2008). Conversely, levels of 2-AG are found to dramatically
decline in the NAcc and PFC throughout adolescence (Ellgren
et al., 2008). These distinct changes in CB1R and eCBs during
adolescence suggest that this system plays both neurodevelop-
mental and morphogenic roles in the maturation of the central
nervous system.
Given the importance of the eCB system in neurodevelopment,
it is likely that externally induced changes in eCB signaling during
adolescence can have profound long-term consequences on func-
tioning in the adult brain. A large body of evidence obtained from
both human studies and animal models suggests that exposure
to cannabis during adolescence increases the likelihood of devel-
oping psychopathology in adulthood (Andreasson et al., 1987;
Rubino et al., 2009b; Abush and Akirav, 2012; Renard et al., 2013).
The psychoactive effects of cannabis are due to the action
of THC on CB1R receptors, which are present at high density
in brain areas that play a role in processing emotional infor-
mation, learning, and memory (e.g., the amygdala, PFC, and
hippocampus) (Herkenham et al., 1990; Marsicano and Lutz,
1999). Perturbations in CB1R signaling in these brain regions
have been linked to psychopathology and emotional dysregu-
lation, which are common among neuropsychiatric disorders,
including anxiety, depression, and schizophrenia (Degenhardt
et al., 2003; Laviolette and Grace, 2006; Ahmad et al., 2013;
Sanchez-Blazquez et al., 2014).
The aim of this review is to summarize published animal
and human studies regarding the long-term consequences of
cannabinoid exposure during adolescence, particularly the effects
on cognitive functioning, emotional behavior, and the risk of
developing a psychiatric disorder in adulthood. The relevant lit-
erature regarding the long-term consequences of cannabinoid
exposure during adolescence in both human and animal studies
is summarized in Table 1 and in Table 2, respectively.
LONG-TERM EFFECTS OF CANNABIS USE DURING
ADOLESCENCE IN HUMANS
COGNITIVE DISORDERS AND NEUROIMAGING ALTERATIONS
Chronically using cannabis before the age of 17 causes more
severe cognitive consequences compared to chronic use later in
adolescence. Indeed, converging lines of evidence suggest that
chronic use before the age of 17 is associated with deficits
in working memory (Schweinsburg et al., 2008, 2010; Becker
et al., 2010b), attention (Ehrenreich et al., 1999; Meier et al.,
2012; Dougherty et al., 2013), decision-making (Dougherty et al.,
2013), visual search (Huestegge et al., 2002), overall and verbal
IQ (Pope et al., 1997; Meier et al., 2012), executive functioning
(Medina et al., 2009; Becker et al., 2010a; Fontes et al., 2011;
Solowij et al., 2012), visuospatial memory (Pope et al., 1997), cog-
nitive inhibition (Fontes et al., 2011), and impulsivity (Dougherty
et al., 2013). The magnitude of these deficits is proportional to
the frequency, dose, and age at onset of use (Medina et al., 2007a;
Schweinsburg et al., 2008, 2010; Becker et al., 2010a; Fontes et al.,
2011; Meier et al., 2012).
Although the precise mechanism through which cannabis
impairs cognition remains unknown, structural abnormalities
have been measured in long-term, heavy cannabis users.
Magnetic resonance imaging (MRI) and positron emission
tomography (PET) studies have reported reduced overall corti-
cal gray matter and increased white matter volume in adolescent
cannabis users compared to users who began using cannabis
in adulthood (Amen and Waugh, 1998; Wilson et al., 2000).
Cannabis use during adolescence has also been attributed to
increased white matter diffusivity in the PFC compared to later
use (Becker et al., 2010a). Functional MRI (fMRI) studies have
revealed abnormal activation in the PFC and parietal brain
regions of adolescent cannabis users (Jager et al., 2010; Becker
et al., 2010a; Gruber et al., 2012). Other groups have also reported
decreased cortical thickness in the right superior PFC, bilateral
insula, and bilateral superior frontal cortices; increased cortical
thickness in the lingual, temporal, inferior parietal, and paracen-
tral regions (Lopez-Larson et al., 2011); and decreased volume in
the right medial orbitofrontal cortex (Churchwell et al., 2010) and
bilateral hippocampus (Yucel et al., 2008; Ashtari et al., 2011) of
adolescent cannabis users without a comorbid psychiatric con-
dition compared to adolescents who do not use cannabis. These
structural changes have been associated with increased executive
dysfunction (Medina et al., 2009; Churchwell et al., 2010) and
verbal memory deficits (Ashtari et al., 2011). In addition, ado-
lescent users of cannabis have reduced cerebral blood flow in
the temporal, insular, and PFC regions, and these reductions in
blood flow are associated with cognitive deficits (Jacobus et al.,
2012). Moreover, converging evidence suggests the presence of
abnormal activation patterns in the PFC, limbic region, pari-
etal region, and cerebellum (Schweinsburg et al., 2008; Becker
et al., 2010a; Lopez-Larson et al., 2012; Vaidya et al., 2012) in
adolescent users of cannabis compared to subjects who do not
use cannabis. Interestingly, using diffusion-weighted MRI and
connectivity mapping, Zalesky et al. (2012) showed that axonal
connectivity was impaired in the right fimbria and the corpus
callosum, two structures that contain abundant levels of cannabi-
noid receptors in the developing brain (Romero et al., 1997;
Molina-Holgado et al., 2002). Zalesky and colleagues also demon-
strated that the age at which regular cannabis use begins is a key
factor in determining the severity of the resulting microstructural
changes in white matter (Zalesky et al., 2012).
Taken together, the above studies suggest that chronic cannabis
use during adolescence can cause long-term structural changes
that are associated with decreased neuronal efficiency in brain
regions that play a central role in learning and memory.
ANXIETY DISORDERS
Anxiety disorders are the most common complications that arise
from chronic heavy cannabis use. Whereas the lifetime prevalence
for anxiety disorder on general population is estimated around
6–17% (Kedzior and Laeber, 2014), this prevalence is increased
in cannabis users with a prevalence up to 20% (Reilly et al.,
1998). A broad and recent meta-analysis (Kedzior and Laeber,
2014) shows that anxiety is significantly positively associated with
the consumption (Odds ratio = 1.24) and misuse of cannabis
(Odds ratio = 1.68). However, only a few studies have examined
the relationship between adolescent cannabis use and long-term
anxiety disorders. Cannabis uses during adolescence can double
the risk of developing anxiety-related symptoms in adulthood,
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particularly if the onset of use was initiated before the age of
15. Moreover, girls are more likely than boys to develop these
symptoms (Patton et al., 2002; Hayatbakhsh et al., 2007).
A recent study examined the relationship between cannabis
use and mental health between the ages of 15 and 29. The authors
found that heavy cannabis use during adolescence was associated
with an increased risk of developing an anxiety disorder later in
life, even if the individual no longer uses cannabis in adulthood
(Degenhardt et al., 2013).
DEPRESSIVE DISORDERS
In many countries, a growing body of evidence supports an
association between cannabis use and depression among young
people. Among cannabis users, the prevalence of depressive disor-
ders is 25%; approximately half of these depressive disorders are
major depression, and the other half are severe mood disorders
(Chabrol et al., 2008). This risk can increase by five-fold, depend-
ing on gender (women seem to be more susceptible than men)
and the age at which cannabis use begins (Grant and Pickering,
1998; Green and Ritter, 2000).
A study conducted among Australians between 13 and 17 years
of age found that adolescents who use cannabis are three times
more likely to meet the criteria for depression later in life com-
pared to adolescents who never used cannabis (Rey et al., 2002).
Another study found that 30% of adolescents who chronically
use cannabis between the ages of 15 and 17 develop depressive
symptoms by the age of 21 (Fergusson et al., 2003). Van Laar
and colleagues confirmed this observation and also reported that
frequent cannabis use increases the risk of developing a depres-
sive disorder (van Laar et al., 2007). In addition, Hayatbakhsh
and colleagues demonstrated that adolescents under the age of
15 who frequently use cannabis are more likely to report symp-
toms of anxiety and depression in early adulthood, particularly
when the researchers took into account cumulative exposure to
cannabis and potentially significant confounding factors such as
maternal smoking and alcohol consumption (Hayatbakhsh et al.,
2007). Finally, a longitudinal study that was conducted in young
Norwegians and followed over a 13-year period (from their early
teens to their late teens) showed a dose-dependent relationship
between chronic cannabis consumption and suicidal tendencies
(i.e., thoughts and attempts) later in life (Pedersen, 2008). Taken
together, these longitudinal studies suggest that early onset and
regular use of cannabis increase the risk of depression later in
life. However, some researchers suggest that both environmental
factors and genetic predisposition play a role in this causal asso-
ciation (Lynskey et al., 2004; Vinod and Hungund, 2006). Indeed,
Lynskey and colleagues observed that twins who were discordant
for cannabis dependence were more likely to develop suicidal
ideation or attempted suicide than their non-cannabis-dependent
co-twins. They also reported that twins discordant for early mari-
juana initiation (before the age of 17) were more likely to attempt
suicide than their non-early-cannabis use co-twins (Lynskey et al.,
2004). Furthermore, post-mortem studies revealed that the den-
sity of CB1R was higher in the PFC of patients with depression
who died by suicide than controls (Vinod and Hungund, 2006).
Finally, increased depressive symptoms in adolescent users of
cannabis were shown to be associated with smaller global white
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matter volume (Medina et al., 2007b), suggesting that cannabis
use during adolescence may disrupt white matter connections
between brain regions that play a role in mood regulation.
These studies put forward that pre-existing genetic factors may
predispose an individual to depression, and that these factors
may be revealed by early cannabis use. Future studies are clearly
needed in order to elucidate the neurobiological mechanisms that
underlie the long-lasting effects of cannabis use on the eventual
onset of depressive disorders.
PSYCHOSIS: FOCUS ON SCHIZOPHRENIA
The psychotic symptoms that have been associated with the use of
cannabis (i.e., the so-called cannabis-induced psychosis) include
a “loss of control,” thought disturbances, feelings of unreal-
ity, apprehension, fear and paranoia, depersonalization, dyspho-
ria, difficulty concentrating, hallucinations, and other perceptual
alterations (Hall and Degenhardt, 2000; Degenhardt and Hall,
2002). The first longitudinal study to demonstrate an association
between adolescent cannabis use and schizophrenia in later life
was conducted in young healthy Swedish subjects (Andreasson
et al., 1987). The authors found that heavy cannabis use at age 18
led to a six-fold increase in the risk of developing schizophrenia
15 years later. In addition, an 11-year longitudinal study of sub-
jects who did not present with pre-existing psychosis found that
cannabis use was associated with an increased risk of develop-
ing schizophrenic symptoms (Arseneault et al., 2002). This study
also revealed that early cannabis consumption (i.e., at age 15)
increased the risk of developing schizophrenic symptoms at age
26 by a factor of four compared to cannabis consumption after
age 18. According to the authors, 8–13% of the patients in their
study might never have developed schizophrenic symptoms had
they not used cannabis (Arseneault et al., 2004). This strong asso-
ciation between adolescent cannabis use and psychotic disorders
later in life was confirmed by Stefanis and colleagues, who found
that both positive and negative psychotic symptoms were more
strongly associated with an onset of cannabis use before the age of
16, regardless of the frequency or duration of use (Stefanis et al.,
2004).
There is still a debate on whether adolescent cannabis use
triggers the onset of schizophrenia in genetically vulnerable indi-
viduals or whether individuals with pre-existing vulnerability for
psychosis are more likely to use cannabis as a means of self-
medication to alleviate some early psychotic symptoms (Dixon
et al., 1990;Mueser et al., 1992; Ferdinand et al., 2005; Degenhardt
et al., 2007). This proposed self-medication explanation does not
account for the association between cannabis use during ado-
lescence and the development of psychosis later in life, as this
relationship is observed more often in the absence of psychologi-
cal distress, and psychological distress does not necessarily predict
cannabis use (Stefanis et al., 2004; Henquet et al., 2005).
In addition, there is overwhelming consensus within the liter-
ature citing a lack of evidence for the self-medication hypothesis,
given that no relationship between early psychotic symptoms and
an increased risk of later cannabis use has been reported (Patton
et al., 2002; Tournier et al., 2003; Verdoux et al., 2003, 2005).
Yet, only a small minority of cannabis users develop psychotic
symptoms. It is therefore likely that both environmental factors
and genetic predisposition play a role in this causal association.
Consistent with this notion, among patients with schizophre-
nia, hypersensitivity to the psychotomimetic effects of cannabis
is associated with early cannabis exposure and a family history of
psychosis (Arendt et al., 2008; Goldberger et al., 2010); moreover,
a recent study of a large sample of students found that sensi-
tivity to the psychotomimetic effects of cannabis appears to be
an intrinsic feature present since the first exposure to cannabis
(Krebs et al., 2014).
NEUROBIOLOGICAL BASIS OF THE LINK BETWEEN
CANNABIS USE AND SCHIZOPHRENIA
CANNABINOID RECEPTORS
Studies in humans support CB1R dysfunction in certain brain
regions of schizophrenic patients, specifically in the cortical
regions that play a role in cognition and memory (i.e., the ante-
rior and posterior cingulate cortices and the dorsolateral PFC),
two functions that are severely compromised in schizophrenia.
Indeed, post-mortem analyses revealed that the density of CB1R
receptors was higher in the dorsolateral PFC and cingulate cor-
tices (both anterior and posterior) of schizophrenic patients com-
pared to controls, and these changes were apparently independent
of recent pre-mortem cannabis use (Dean et al., 2001; Zavitsanou
et al., 2004; Newell et al., 2006).
ENDOCANNABINOIDS
Clinical studies suggest that in addition to altering CB1R func-
tion, schizophrenic patients have changes in their eCB lev-
els, particularly AEA. Indeed, AEA levels are higher in the
cerebrospinal fluid of non-medicated paranoid schizophrenic
patients than in healthy subjects, irrespective of recent cannabis
use (Leweke et al., 1999). Interestingly, other lipid molecules,
including oleoylethanolamide and palmitoylethanolamide, were
not increased in these patients, excluding the likelihood
of schizophrenia-related changes in general lipid signaling
(Giuffrida et al., 2004).
Treating schizophrenic patients with classic antipsychotics
(i.e., dopamine D2 receptor antagonists) lowers AEA levels to
normal. Because paranoid schizophrenia is characterized pri-
marily by predominantly positive symptoms due to hyper-
dopaminergic neurotransmission (Oades et al., 2002), AEA has
been suggested to play an adaptive role, counteracting the
dopaminergic abnormalities in schizophrenia, thus reinforc-
ing the existence of dysregulated AEA signaling in schizophre-
nia. Another study by the same group found that frequent
cannabis use down-regulates AEA levels in the cerebrospinal
fluid of schizophrenic patients, but not healthy controls (Leweke
et al., 2007). These results indicate that frequent cannabis expo-
sure may lead to the down-regulation of AEA signaling (by
decreasing AEA biosynthesis and/or increasing AEA degrada-
tion) in the central nervous system of schizophrenic patients,
but not healthy patients. This down-regulation of AEA might
disrupt AEA’s control over dopaminergic neurotransmission,
thereby precipitating psychosis. Accordingly, alterations in AEA
signaling might be an important component of the puta-
tive mechanism through which cannabis precipitates psychotic
symptoms.
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GENETIC VULNERABILITY TO CANNABIS
A growing body of data in recent years supports the notion
that genetics plays a clear role in the association between
early cannabis exposure and an increased risk of developing
schizophrenia. Following the first published report of an associa-
tion between a CNR1 receptor polymorphism and cannabis abuse
in schizophrenia (Leroy et al., 2001), a second study of a Japanese
cohort found that a polymorphism in the CNR1 gene (which
encodes the CB1R receptor) may be associated with an increased
risk of developing hebephrenic (i.e., disorganized) schizophrenia
(Ujike et al., 2002). This form of schizophrenia is characterized
primarily by negative symptoms that resemble the amotivational
features commonly observed following chronic cannabis con-
sumption. However, the current state of the literature does not
suggest that this polymorphism would be a vulnerability factor
for hebephrenic schizophrenia and further studies are needed to
confirm CNR1 polymorphisms as a genetic risk for hebephrenic
schizophrenia.
A more recent study evaluated interactions between CNR1
polymorphisms, heavy cannabis use, cerebral volume and cogni-
tive function (Ho et al., 2011). Authors compared schizophrenia
patients with heavy cannabis use and schizophrenia patients with-
out heavy cannabis use. First, they observed that schizophrenia
patients with cannabis abuse had smaller fronto-temporal white
matter volumes than patients without heavy cannabis use. In
addition, they found that schizophrenia patients with specific
CNR1 polymorphisms (specifically rs12720071 SNP G-allele car-
riers) were more vulnerable to the impact of heavy cannabis
use, as they showed greater white matter volume decrease and
cognitive impairment than patients without heavy cannabis use.
These results are suggestive of gene-environment interactions for
conferring phenotypic abnormalities in schizophrenia (Ho et al.,
2011).
The relationship between adolescent cannabis use and psy-
chotic symptoms may also be attributed to a functional poly-
morphism in the catechol-O-methyltransferase (COMT) gene,
which encodes an enzyme that degrades catecholamines such
as dopamine (DA). The human COMT gene has two allelic
variants that code for either a valine or a methionine at
codon 158. The functional COMT valine 158 variant catab-
olizes synaptic DA faster than the COMT methionine 158
variant (Lachman et al., 1996). Caspi and colleagues found
that carriers of the COMT valine 158 allele who use cannabis
are more likely to exhibit psychotic symptoms and develop a
schizophrenic disorder; in contrast, cannabis consumption had
no such effect on individuals with two copies of the methion-
ine variant (Caspi et al., 2005). Finally, increased COMT activity
may underlie the decrease in synaptic DA levels that con-
tributes to the development of cognitive disorders (Chen et al.,
2004).
Polymorphisms in the AKT1 gene may play a role in psy-
chosis induced by early cannabis use. AKT1 is a serine/threonine
kinase that helps regulate dopaminergic signaling cascades.
Cannabinoids can activate the AKT1 pathway via CB1R receptors.
Indeed, Decoster and colleagues recently reported that a genetic
variation in the AKT1 gene may mediate cannabis-associated
effects on the expression of psychosis via a cannabinoid-regulated
AKT1/GSK-3 signaling mechanism that lies downstream of the
dopamine D2 receptor (Decoster et al., 2011).
Finally, a recent study of nearly 1200 young healthy students
revealed that the psychotomimetic effects at first cannabis use
were associated with CNR1 variants but not with COMT or
AKT1 variants (Krebs et al., 2014). This finding supports the
notion that individual variability in the psychotomimetic effect
of cannabis may be attributed to specific genetic backgrounds
that influence an individual’s first response to cannabis, poten-
tially revealing increased risk of developing psychosis later in life
in those individuals (Krebs et al., 2014).
Taken together, these studies confirm that cannabis
use—particularly during adolescence—can contribute to
the emergence of psychotic disorders in genetically vulnerable
individuals, supporting the “two-hit” hypothesis, which posits
that both genetics and environmental factors encountered early
in life increase the individual’s risk of developing a psychiatric
disorder (see below).
STUDYING THE LONG-TERM EFFECTS OF CANNABINOID
EXPOSURE DURING ADOLESCENCE USING ANIMAL
MODELS
Animal models are useful tools for investigating the long-term
behavioral effects of cannabis exposure during adolescence. To
develop a suitable animal model, one must first take into con-
sideration the obvious differences in developmental ontogeny
between the animal species and human patients. Adolescence
has a broad developmental border in both humans and animals.
In rodents, adolescence ranges from postnatal day 28 (PND28)
to PND42 (Spear, 2000), and it can be subdivided into spe-
cific phases such as early adolescence (beginning at PND28),
mid-adolescence (beginning at PND38), and late adolescence
(beginning at PND49) (Figure 1).
The relevant literature regarding the long-term consequences
of cannabinoid exposure during adolescence in rats is summa-
rized in Table 2.
COGNITIVE IMPAIRMENTS
Chronically exposing adolescent rats (of either gender) to CB1R
agonists (including THC, WIN55,212-2, and CP55,950) induces
short-term memory impairment measured using the object
recognition task (Schneider and Koch, 2003; O’Shea et al., 2006;
Quinn et al., 2008; Schneider et al., 2008; Llorente-Berzal et al.,
2013; Renard et al., 2013; Zamberletti et al., 2014). In contrast,
chronic cannabinoid exposure to adult rats has no long-term sig-
nificant effect on this cognitive function (Schneider and Koch,
2003; Quinn et al., 2008; Renard et al., 2013). However, one
study demonstrated that chronic THC treatment in adult mice
impairs performance in the object recognition task for 4 days fol-
lowing the last THC injection and these deleterious effects were
shown to be prevented by a pre-treatment with Temsirolimus, an
mTOR inhibitor, suggesting a role for mTOR in the THC-induced
long-lasting memory impairment (Puighermanal et al., 2013).
Similarly, deficits in spatial working memory have been
observed in adult rats that were exposed to CB1R agonists dur-
ing adolescence; these deficits were detected using the radial
maze task (Rubino et al., 2009a,b) and the object location task
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FIGURE 1 | Schematic overview of the various stages of adolescence in
rats. To model the effects of cannabinoid exposure at different
developmental stages, rats can be treated chronically throughout the entire
adolescent period (from PND28 through PND61) or during specific stages of
adolescence, including early adolescence (beginning at PND28),
mid-adolescence (beginning at PND38), or late adolescence (beginning at
PND49). The long-term effects of adolescent cannabinoid exposure can then
be measured in adulthood. PND, postnatal day.
(Abush and Akirav, 2012; Renard et al., 2013). With respect to
the potential neurobiological substrates that may underlie this
phenomenon, these cognitive deficits have been correlated to
reduced expression of several proteins in the hippocampus and
in the PFC, including synaptic plasticity proteins (PSD95 and
synaptophysin), cytoskeletal and structural proteins related to
degenerative and oxidative changes, NMDA receptors, glutamic
acid decarboxylase 67 (GAD 67), glial fibrillary acidic proteins
(GFAP), and activity-regulated cytoskeletal-associated protein
(Arc) (Quinn et al., 2008; Rubino et al., 2009a,b; Llorente-Berzal
et al., 2013; Zamberletti et al., 2014). In addition, adult rats that
were treated with cannabinoids during adolescence have reduced
total dendritic length, arborization, and spine numbers in the
dentate gyrus (Rubino et al., 2009b). Interestingly, exposure to
cannabinoids during adolescence does not appear to induce long-
lasting memory impairments in adult rats (measured using the
Morris water maze) of either gender (Cha et al., 2007; Higuera-
Matas et al., 2009). Overall, the deleterious cognitive effects of
early cannabinoid exposure point to long-lasting impairments
in short-term—rather than long-term—information processing.
However, further research is needed in order to understand these
differential changes in the temporal aspects of memory.
Taken together, these findings obtained from many animal
studies support the results obtained from human studies and con-
firm that adolescence is a highly critical period with long-term
downstream effects on cognitive processing.
ANXIETY-LIKE BEHAVIOR
With respect to anxiety, the results obtained from animal studies
are less consistent than cognitive function, although this lack of
consistency may be due to the specific developmental period in
which cannabinoids are administered and/or the behavioral test
used to measure anxiety. Chronic treatment with the cannabinoid
agonist CP-55,940 from PND35 to PND45 decreased anxiety lev-
els assessed using the open-field test and the elevated plus maze
(Biscaia et al., 2003). However, no changes in plasma corticos-
terone levels were found in the adult rats, suggesting “normal”
function and activity of the hypothalamo-hypophyso-cortico-
adrenal axis. In addition, chronic treatment with various CB1R
agonists (e.g., THC, CP-55,940, and WIN55,212-2) decreased
anxiety levels in adult rats assessed using the social interaction test
(O’Shea et al., 2006; Quinn et al., 2008; Zamberletti et al., 2014).
Conversely, treating rats chronically with CP-55,940 from
PND28 to PND38 or with THC from PND28 to PND45 led to
an increase in anxiety levels at adulthood, measured using the
elevated plus maze (Higuera-Matas et al., 2009) or the open-field
test, respectively (Llorente-Berzal et al., 2013). Similarly, chroni-
cally treating rats with high doses of WIN55,212-2 from PND30
to PND50 induced anxiety-like effects at adulthood, measured
using the novelty-suppressed feeding test (Bambico et al., 2010).
DEPRESSIVE-LIKE BEHAVIOR
Experimental studies revealed that exposing adolescent rats to
cannabinoids leads to an immediate dysregulation of emotional
processes and induces a depressive-like phenotype later in life.
Treating adolescent (PND35–PND45) rats with WIN55,212-2 or
THC led to decreased sucrose preference (a measure of anhedo-
nia) in adulthood (Rubino et al., 2008; Bambico et al., 2010).
Subjecting adolescent cannabinoid-treats rats to the forced-swim
test also revealed a depressive phenotype, and these effects appear
to be stronger in female rats (Rubino et al., 2008; Bambico
et al., 2010; Zamberletti et al., 2014). These findings suggest that
cannabinoid exposure during adolescence may affect the sus-
ceptibility to develop a mood disorder later in life, and these
animal models appear to recapitulate the gender differences that
are well-documented among human patients with depression.
Investigating the neurobiological mechanisms that underlie the
change in emotion induced by adolescent cannabinoid exposure,
Rubino and colleagues found a decrease in CB1R expression in
the amygdala, ventral tegmental area, and NAcc, thereby demon-
strating a role for CB1R receptors in the regulation of emotional
response (Rubino et al., 2008). These changes in CB1R expres-
sion were accompanied by changes in the levels of CREB protein
in the hippocampus, NAcc, and PFC (Rubino et al., 2008). More
recently, Bambico and colleagues reported that treating adoles-
cent rats—but not adult rats—withWIN55,212-2 alters midbrain
neuronal firing (Bambico et al., 2010). Specifically, adolescent
cannabinoid treatment resulted in hyperactivity of noradrenergic
neurons concomitant with hypoactivity of serotonergic neurons
(Bambico et al., 2010). Such neuroadaptations are consistent with
enhanced depressive-like behavior due to cannabinoid exposure
during adolescence.
PSYCHOTIC-LIKE BEHAVIOR
To date, animal studies regarding psychotic symptoms have
focused on disruptions in ∗∗prepulse inhibition (PPI). Impaired
PPI is widely accepted as an endophenotype of schizophrenia with
high translational validity (Braff et al., 2001; Perry et al., 2001).
Chronically treating adolescent rats (PND40–PND65) with
the cannabinoid agonist WIN55,212-2 induced long-lasting
www.frontiersin.org November 2014 | Volume 8 | Article 361 | 9
Renard et al. Long-term effects of adolescence cannabis use
sensorimotor gating impairment in adulthood (i.e., 85 days after
treatment), measured using the PPI test (Schneider and Koch,
2003; Wegener and Koch, 2009); in contrast, chronically treat-
ing adult rats did not affect PPI. These deficits were correlated
with changes in basal neuronal activity (i.e., c-Fos activity) in the
NAcc, amygdala, caudate putamen, and hippocampus (Wegener
and Koch, 2009). In contrast, other groups reported no changes in
PPI after chronically exposing adolescent rats (PND35–PND45)
to THC (Bortolato et al., 2014). This discrepancy may be due to
the adolescent period in which the rats were treated and/or the
cannabinoid compound that was administered. These differences
in results may also reflect differences in the genetic backgrounds
of the rats used in these studies (for example, Bortolato and
colleagues used Lewis rats, whereas Schneider and colleagues
used Wistar rats). Indeed, strain differences have been found to
play a critical role in modulating the acoustic startle reflex and
sensorimotor gating in rats (Hsieh et al., 2006).
THE “TWO-HIT” NEURODEVELOPMENTAL ANIMAL MODEL OF
SCHIZOPHRENIA
As discussed above, the “two-hit hypothesis” of schizophre-
nia posits that a prenatal genetic or environmental “first hit”
increases the individual’s vulnerability to a “second hit” later
in life, thereby significantly increasing the risk of developing
schizophrenic symptoms (Bayer et al., 1999). To test this hypoth-
esis, COMT-knockout mice (the “first hit”) were exposed to THC
during adolescence (the “second hit”); this two-hit approach
induced long-lasting impairments in exploration, spatial working
memory, and anxiety (O’Tuathaigh et al., 2010), as well as deficits
in PPI, habituation to the acoustic startle response, sociability,
and social novelty preference (O’Tuathaigh et al., 2012). Exposing
adolescent COMT-knockout mice to THC also decreased the size
of dopaminergic and GABAergic cells in the ventral tegmental
area and PFC, respectively, and increased CB1R expression in
the hippocampus (Behan et al., 2012). These results reinforce the
notion that an individual’s risk of developing schizophrenia may
be influenced by interactions between genetic-based changes in
DA catabolism and cannabis exposure. These finding also sug-
gest how COMT deletion and adolescent cannabis use may work
together to modulate the function of neurotransmitter systems
implicated in schizophrenia.
Other studies have also revealed an interesting interaction
between cannabis exposure and a mutation in the neuregulin
1 (Nrg1) gene. Mice that are heterozygous for the transmem-
brane domain Nrg1 mutant (Nrg1 HET mice) appeared to be
more sensitive to the behavioral effects of acute THC exposure
than their wild-type littermates (Boucher et al., 2007a; Long
et al., 2010). Following chronic exposure to THC, Nrg HET
mice developed tolerance to cannabinoid-induced hypothermia
and locomotor suppression more rapidly than wild-type mice
(Boucher et al., 2011). Conversely, wild-type mice (but not Nrg1
HET) mice developed tolerance to cannabinoid-induced anxiety,
whereas Nrg1 HET mice showed a persistent anxiogenic response
to chronic cannabinoid exposure. Cannabinoid exposure (either
acute or chronic) also selectively induced the expression of Fos
transcription factors in the lateral septum of Nrg1 HET mice, but
not wild-type mice (Boucher et al., 2007b, 2011). In addition,
chronically exposing adolescent Nrg1 HET mice to THC exacer-
bated their hyperlocomotor phenotype and induced differential
effects in the density of NMDA, CB1, and 5-HT2A receptors in
brain regions that are relevant to schizophrenia, particularly the
hippocampus (Long et al., 2013). More recently, these researchers
expanded their previous findings, reporting that chronic ado-
lescent exposure to THC induces the differential expression of
proteins involved in NMDA receptor trafficking to the synaptic
membrane, lipid raft stabilization of synaptic NMDA receptors,
and homeostatic responses that dampen excitotoxicity (Spencer
et al., 2013). These observations suggest an interaction between
the cannabinoid system and Nrg1 signaling and indicate that
altered expression of the Nrg1 gene can modulate the behavioral
consequences of THC exposure during adolescence.
Similarly, Schneider and Koch (2007) reported that adoles-
cent cannabinoid exposure induces stronger deficits in both
short-term memory and social behavior in rats that received a
neonatal PFC lesion. In addition, exposure to THC during adoles-
cence exacerbated (i) the short-term memory deficit in rats that
were chronically pretreated with PCP (measured using the object
recognition test) (Vigano et al., 2009), and (ii) the disruption in
PPI in socially isolated rats (Malone and Taylor, 2006).
Taken together, these studies of the interaction between genetic
factors and environmental factors help elucidate the putative
mechanisms underlying the etiopathogenesis of schizophrenia
and may facilitate the discovery of new therapeutic targets.
CONCLUSIONS
A considerable body of evidence obtained from both human
studies and animal models suggests that cannabis use during ado-
lescence increases the risk of developing a psychiatric disorder in
adulthood, including anxiety, depression, and schizophrenia. The
psychiatric disorders discussed in this review are multifactorial in
origin, and the transition from adolescent cannabis use to sub-
sequent psychiatric illness may also involve both genetic factors
and environmental factors. The developmental period of initi-
ation, the frequency, and the duration of cannabis use, as well
as any underlying psychiatric pathology, may all play a critical
role in the development of a psychiatric disorder. In addition,
compelling evidence suggests that some adolescents are more sus-
ceptible to the long-term effects of cannabis use than others, and
this may be due to differences in genetic vulnerability, including
polymorphisms in the genes that play a role in the development
of psychiatric diseases. However, whether early cannabis use is
related to a pre-existing pathology that is exacerbated by drug use
remains an open question.
Disrupting the eCB system during development may affect
several neurotransmitter systems. Indeed, CB1R receptors are
presynaptic and are expressed primarily in GABAergic interneu-
rons and pyramidal neurons (Marsicano and Lutz, 1999;Manzoni
and Bockaert, 2001; Morozov and Freund, 2003). By modulating
the release of GABA and glutamate, CB1R receptors help pre-
vent excess neuronal excitation and inhibition (Marsicano et al.,
2003; Kano et al., 2009; Katona, 2009). Repeated excessive CB1R
stimulation by THC during adolescence may shift the balance of
GABAergic inhibitory input on pyramidal neurons.We can there-
fore speculate that exposure to cannabinoids during adolescence
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might interfere with the development of neuronal processes in
the still-developing adolescent brain, thus leading to changes that
ultimately affect brain connectivity, function, and behavior.
Longitudinal studies using neuroimaging and genetic
approaches to evaluate adolescents prior to the start of chronic
cannabis use are needed. In addition, studies using animal
models are needed in order to further investigate the role of the
endocannabinoid system in adolescence, as well as the molecular
and neurochemical mechanisms that underlie the deleterious
effects of cannabinoid exposure during adolescence. Such studies
would greatly enhance our understanding of the propensity
for adolescent cannabis use to facilitate the development of
psychiatric disease later in life.
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